ANO1 and head and neck squamous cell carcinoma: Since EGFR is overexpressed in 90% of HNSCC cases11, and its overexpression is associated with poor prognosis12,13, targeting Ano1 might represent a preferentially attractive therapeutic strategy for 11q13 amplified HNSCC14,15.